Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.8, 2011-06, pp. : 1249-1258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease

Current Medicinal Chemistry, Vol. 15, Iss. 24, 2008-10 ,pp. : 2433-2455

Bentham Science Publishers

Access to resources Recommend Favorite

Disease-Modifying Therapies for Osteoarthritis: Current Status

By Marc Fajardo Paul E. Di Cesare

Drugs & Aging, Vol. 22, Iss. 2, 2005-01 ,pp. : 141-161

Adis International

Access to resources Recommend Favorite

Disease-Modifying Therapies in Frontotemporal Lobar Degeneration

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 1008-1020

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting a Genetic Killer: Novel Disease-Modifying Therapies for Cystic Fibrosis

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 4, 2006-01 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis: A Comprehensive Overview

By Johnston Jessica

Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. : 1195-1211

Adis International

Access to resources Recommend Favorite